These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 23621892)

  • 1. The impact of Medicare prescription drug coverage on the use of antidementia drugs.
    Fowler NR; Chen YF; Thurton CA; Men A; Rodriguez EG; Donohue JM
    BMC Geriatr; 2013 Apr; 13():37. PubMed ID: 23621892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical Treatment for Alzheimer's Disease and Related Dementias: Utilization and Disparities.
    Barthold D; Joyce G; Ferido P; Drabo EF; Marcum ZA; Gray SL; Zissimopoulos J
    J Alzheimers Dis; 2020; 76(2):579-589. PubMed ID: 32538845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
    Blumberg DM; Prager AJ; Liebmann JM
    JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial and Ethnic Differences in Initiation and Discontinuation of Antidementia Drugs by Medicare Beneficiaries.
    Thorpe CT; Fowler NR; Harrigan K; Zhao X; Kang Y; Hanlon JT; Gellad WF; Schleiden LJ; Thorpe JM
    J Am Geriatr Soc; 2016 Sep; 64(9):1806-14. PubMed ID: 27549029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.
    Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
    J Manag Care Spec Pharm; 2014 Aug; 20(8):862-76. PubMed ID: 25062080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Medicare Part D on Ethnoracial Disparities in Antidementia Medication Use.
    Lind KE; Hildreth K; Lindrooth R; Morrato E; Crane LA; Perraillon MC
    J Am Geriatr Soc; 2018 Sep; 66(9):1760-1767. PubMed ID: 30095169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescription coverage, use and spending before and after Part D implementation: a national longitudinal panel study.
    Safran DG; Strollo MK; Guterman S; Li A; Rogers WH; Neuman P
    J Gen Intern Med; 2010 Jan; 25(1):10-7. PubMed ID: 19882193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of Medicare Part D on drug and medical spending.
    Zhang Y; Donohue JM; Lave JR; O'Donnell G; Newhouse JP
    N Engl J Med; 2009 Jul; 361(1):52-61. PubMed ID: 19571283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Patterns with Antidementia Drugs in the United States: Medicare Cohort Study.
    Koller D; Hua T; Bynum JP
    J Am Geriatr Soc; 2016 Aug; 64(8):1540-8. PubMed ID: 27341454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease.
    Mantri S; Fullard M; Gray SL; Weintraub D; Hubbard RA; Hennessy S; Willis AW
    JAMA Neurol; 2019 Jan; 76(1):41-49. PubMed ID: 30285047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Medicare Part D Benzodiazepine Coverage Expansion With Changes in Fall-Related Injuries and Overdoses Among Medicare Advantage Beneficiaries.
    Maust DT; Lin LA; Goldstick JE; Haffajee RL; Brownlee R; Bohnert ASB
    JAMA Netw Open; 2020 Apr; 3(4):e202051. PubMed ID: 32242907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
    DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
    JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Medicare Part D on Prescription Drug Spending and Health Care Use: 6 Years of Follow-up, 2007-2012.
    Park T; Jung J
    J Manag Care Spec Pharm; 2017 Jan; 23(1):5-12. PubMed ID: 28025927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The costs of Alzheimer's disease and the value of effective therapies.
    Stefanacci RG
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S356-62. PubMed ID: 22214393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug benefit changes under Medicare Advantage Part D: heterogeneous effects on pharmaceutical use and expenditures.
    Ettner SL; Steers WN; Turk N; Quiter ES; Mangione CM
    J Gen Intern Med; 2011 Oct; 26(10):1195-200. PubMed ID: 21710313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Medicare Part D on drug affordability and use: Are seniors with prior high out-of-pocket drug spending affected more?
    Mott DA; Thorpe JM; Thorpe CT; Kreling DH; Gadkari AS
    Res Social Adm Pharm; 2010 Jun; 6(2):90-9. PubMed ID: 20511108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative cardiovascular safety of dementia medications: a cross-national study.
    Fosbøl EL; Peterson ED; Holm E; Gislason GH; Zhang Y; Curtis LH; Køber L; Iwata I; Torp-Pedersen C; Setoguchi S
    J Am Geriatr Soc; 2012 Dec; 60(12):2283-9. PubMed ID: 23176182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Medicare Part D on the Proportion of Out-of-Pocket Prescription Drug Costs Among Older Adults With Diabetes.
    Choi YJ; Jia H; Gross T; Weinger K; Stone PW; Smaldone AM
    Diabetes Care; 2017 Apr; 40(4):502-508. PubMed ID: 27803119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.